Literature DB >> 1263566

Methylprednisolone. Pharmacologic doses in shock lung syndrome.

A Sladen.   

Abstract

Patients with shock lung syndrome were identified as those who developed acute respiratory failure after a profound episode of hypotension secondary to hemorrhagic, gram-negative, or endotoxic shock. In this study, each of the 10 patients with shock lung syndrome received methylprednisolone sodium succinate, 30 mg. per kilogram, intravenously every 6 hours for 48 hours. In addition, all patients were supported with mechanical ventilation, with or without positive end-expiratory pressure (PEEP). Arterial oxygenation improved markedly, and pulmonary edema resolved in all patients. Nine were discharged from the hospital and one died subsequently of disseminated intravascular coagulation. This study demonstrated a significant improvement in mortality rate with repeated pharmacologic doses of methylprednisolone compared to previously reported mortality rates of 60 to 90 per cent in patients with shock lung syndrome treated without repeated pharmacologic doses of steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1263566

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  11 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

Review 2.  Corticosteroids, nonsteroidal anti-inflammatory drugs, and naloxone in the sepsis syndrome.

Authors:  W M Long; C L Sprung
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 3.  Current concepts in the management of the adult respiratory distress syndrome.

Authors:  J A Weigelt
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

Review 4.  Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit.

Authors:  S Westaby
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

5.  Steroids decrease granulocyte membrane fluidity, while phorbol ester increases membrane fluidity. Studies using electron paramagnetic resonance.

Authors:  H R Lamche; P T Silberstein; A C Knabe; D D Thomas; H S Jacob; D E Hammerschmidt
Journal:  Inflammation       Date:  1990-02       Impact factor: 4.092

6.  Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro.

Authors:  K M Skubitz; P R Craddock; D E Hammerschmidt; J T August
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

7.  The adult respiratory distress syndrome bronchogenic pulmonary tuberculosis.

Authors:  R A Dyer; P D Potgieter
Journal:  Thorax       Date:  1984-05       Impact factor: 9.139

8.  Synergy among agents inhibiting granulocyte aggregation.

Authors:  D E Hammerschmidt; P J Flynn; P A Coppo; K M Skubitz; H S Jacob
Journal:  Inflammation       Date:  1982-06       Impact factor: 4.092

9.  [Early PEEP for improvement of prognosis in patients with acute respiratory insufficiency (author's transl)].

Authors:  L S Weilemann; H P Schuster; C J Schuster; C Rey; J Majdandzic
Journal:  Klin Wochenschr       Date:  1981-06-15

10.  Steroids inhibit activation of the alternative-amplification pathway of complement.

Authors:  B D Packard; J M Weiler
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.